Global Intermittent Claudication Therapeutics Pipeline Review, H2 2016: 4 Companies & 5 Drug Profiles - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Intermittent Claudication - Pipeline Review, H2 2016" report to their offering.

'Intermittent Claudication - Pipeline Review, H2 2016'; Intermittent Claudication pipeline therapeutics constitutes close to 5 molecules. which approximately 5 molecules are developed by Companies.

Intermittent Claudication Intermittent claudication is caused by narrowing or blockage in the main artery that takes blood to leg. Symptoms include burning or tingling sensation, decreased or absent pulse in the lower limb, pale or bluish skin, poor hair growth on the legs and sores or wounds on the lower limb that heal slowly, poorly. Risk factors include smoking, high cholesterol, high blood pressure, obesity, diabetes, age and family history.

The report 'Intermittent Claudication - Pipeline Review, H2 2016' outlays comprehensive information on the therapeutics under development for Intermittent Claudication, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews of key players involved in therapeutic development for Intermittent Claudication and features dormant and discontinued projects. Currently, The molecules developed by Companies in Phase II and Discovery stages are 4 and 1 respectively.

Key Topics Covered:

  1. Introduction
  2. Intermittent Claudication Overview
  3. Therapeutics Development
  4. Pipeline Products for Intermittent Claudication - Overview
  5. Pipeline Products for Intermittent Claudication - Comparative Analysis
  6. Intermittent Claudication - Therapeutics under Development by Companies
  7. Intermittent Claudication - Therapeutics under Investigation by Universities/Institutes
  8. Intermittent Claudication Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Intermittent Claudication - Products under Development by Companies
  13. Intermittent Claudication - Products under Investigation by Universities/Institutes
  14. Intermittent Claudication - Companies Involved in Therapeutics Development
  • ID Pharma Co., Ltd.
  • Kowa Company, Ltd.
  • Nuo Therapeutics, Inc.
  • Pluristem Therapeutics Inc.

For more information about this report visit http://www.researchandmarkets.com/research/xvxh3r/intermittent

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Cardiovascular Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Cardiovascular Drugs